RiverPark Advisors LLC Has $1.36 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

RiverPark Advisors LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 58.1% in the third quarter, Holdings Channel.com reports. The fund owned 20,639 shares of the medical research company’s stock after buying an additional 7,583 shares during the quarter. RiverPark Advisors LLC’s holdings in Edwards Lifesciences were worth $1,362,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of EW. Cetera Advisors LLC lifted its position in Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after acquiring an additional 24,242 shares in the last quarter. BDF Gestion bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $5,148,000. Tidal Investments LLC lifted its position in Edwards Lifesciences by 54.7% during the 1st quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock worth $2,890,000 after buying an additional 10,700 shares in the last quarter. Raymond James & Associates lifted its position in Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after buying an additional 50,124 shares in the last quarter. Finally, AIA Group Ltd lifted its position in Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after buying an additional 358,556 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock valued at $2,744,438 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on EW shares. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Stifel Nicolaus lowered their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Robert W. Baird lowered their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Citigroup lowered their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. Finally, Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Up 2.4 %

EW stock opened at $67.76 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $67.44 and its 200 day moving average is $76.18. The stock has a market cap of $39.96 billion, a price-to-earnings ratio of 9.78, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.59 earnings per share. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.